Literature DB >> 19802895

Recurrent copy number alterations in BRCA1-mutated ovarian tumors alter biological pathways.

Karin Leunen1, Olivier Gevaert, Anneleen Daemen, Vanessa Vanspauwen, Geneviève Michils, Bart De Moor, Philippe Moerman, Ignace Vergote, Eric Legius.   

Abstract

Array CGH was used to identify recurrent copy number alterations (RCNA) characteristic of either BRCA1-related or sporadic ovarian cancer. After preprocessing, both groups of patients were modeled using a recurrent Hidden Markov Model to detect RCNA. RCNA with a probability higher than 80% were called. After removing RCNA present in both groups, the genes present in the remaining RCNA were investigated for enrichment of pathways from external databases. More RCNA were observed in the BRCA1 group, and they display more losses than gains compared to the sporadic group. When focusing on the type of RCNA, no significant difference in length was seen for the gains, but there was a statistically significant difference for the losses. In the sporadic group, a great proportion of the altered regions contain genes known to have a function in cell adhesion and complement activation, whereas the BRCA1 samples are characterized by alterations in the HOX genes, metalloproteinases, tumor suppressor genes, and the estrogen-signaling pathways. We conclude that BRCA1 ovarian tumors present a different type, number, and length of RCNA; a huge amount of the genome is lost, resulting in important genomic instability. Moreover, important biological pathways are altered differentially when compared to the sporadic group.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19802895     DOI: 10.1002/humu.21135

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  7 in total

1.  Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing.

Authors:  Joke Reumers; Peter De Rijk; Hui Zhao; Anthony Liekens; Dominiek Smeets; John Cleary; Peter Van Loo; Maarten Van Den Bossche; Kirsten Catthoor; Bernard Sabbe; Evelyn Despierre; Ignace Vergote; Brian Hilbush; Diether Lambrechts; Jurgen Del-Favero
Journal:  Nat Biotechnol       Date:  2011-12-18       Impact factor: 54.908

Review 2.  Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.

Authors:  Marieke A Vollebergh; Jos Jonkers; Sabine C Linn
Journal:  Cell Mol Life Sci       Date:  2011-09-16       Impact factor: 9.261

3.  Identifying master regulators of cancer and their downstream targets by integrating genomic and epigenomic features.

Authors:  Olivier Gevaert; Sylvia Plevritis
Journal:  Pac Symp Biocomput       Date:  2013

4.  Inherited variation in miR-290 expression suppresses breast cancer progression by targeting the metastasis susceptibility gene Arid4b.

Authors:  Natalie Goldberger; Renard C Walker; Chang Hee Kim; Scott Winter; Kent W Hunter
Journal:  Cancer Res       Date:  2013-02-27       Impact factor: 12.701

5.  Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.

Authors:  Sébastien Toffoli; Isabelle Bar; Fadi Abdel-Sater; Paul Delrée; Pascale Hilbert; Frédéric Cavallin; Fabrice Moreau; Wim Van Criekinge; Magali Lacroix-Triki; Mario Campone; Anne-Laure Martin; Henri Roché; Jean-Pascal Machiels; Javier Carrasco; Jean-Luc Canon
Journal:  Breast Cancer Res       Date:  2014-11-22       Impact factor: 6.466

6.  Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients.

Authors:  Marta M Kamieniak; Daniel Rico; Roger L Milne; Ivan Muñoz-Repeto; Kristina Ibáñez; Miguel A Grillo; Samuel Domingo; Salud Borrego; Alicia Cazorla; José M García-Bueno; Susana Hernando; Jesús García-Donas; Elena Hernández-Agudo; Teresa Ramón Y Cajal; Luis Robles-Díaz; Ivan Márquez-Rodas; Maite Cusidó; Raquel Sáez; Carmen Lacambra-Calvet; Ana Osorio; Miguel Urioste; Juan C Cigudosa; Luis Paz-Ares; José Palacios; Javier Benítez; María J García
Journal:  Mol Oncol       Date:  2014-10-05       Impact factor: 6.603

7.  DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas.

Authors:  M M Kamieniak; I Muñoz-Repeto; D Rico; A Osorio; M Urioste; J García-Donas; S Hernando; L Robles-Díaz; T Ramón Y Cajal; A Cazorla; R Sáez; J M García-Bueno; S Domingo; S Borrego; J Palacios; M A van de Wiel; B Ylstra; J Benítez; M J García
Journal:  Br J Cancer       Date:  2013-04-04       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.